1. Home
  2. Companies
  3. CHM
  4. Material Events

Chimeric Therapeutics (ASX:CHM) — Material Events

ASX:CHM · 17 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 13 articles Notable 4 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
13
Chimeric Therapeutics Narrows Loss, Advances Pioneering Cell TherapiesMedium
Chimeric Therapeutics reports reduced loss, advances clinical trials, and strengthens funding
29 Aug 2025 ·Annual Report ·85
Chimeric Therapeutics Accelerates Clinical Trials with FDA Fast Track and $6.6M RaiseMedium
Chimeric Therapeutics advances clinical trials, secures FDA Fast Track, raises $6.6M placement
29 July 2025 ·Quarterly Activities Report ·85
Chimeric Therapeutics Sees Tumour Shrinkage in Early CHM CDH17 Trial ResultsMedium
Chimeric Therapeutics reports tumor shrinkage and disease control in CHM CDH17 Phase 1/2 trial with Dose Level 2 deemed safe
29 Sept 2025 ·Clinical Trial Update ·85
Chimeric Therapeutics Unveils Promising AML Trial Results with CORE-NK TherapyMedium
Chimeric Therapeutics reports encouraging Phase 1B ADVENT-AML trial results with CORE-NK therapy
2 Oct 2025 ·Clinical Trial Update ·85
Chimeric Therapeutics Shows 82% Disease Stability in Early CHM CDH17 CAR-T TrialMedium
Chimeric Therapeutics reports positive Phase 1/2 data for CHM CDH17 CAR-T in GI cancers
1 June 2026 ·Clinical Trial Update ·85
Chimeric Therapeutics Secures $8.4M to Advance Promising CAR-T and NK Cell TrialsMedium
Chimeric Therapeutics advances clinical trials, secures $8.4M funding, FDA grants orphan drug status
28 Jan 2026 ·Quarterly Activities Report ·85
Chimeric Therapeutics Secures $8.4M to Propel CHM CDH17 CAR-T Trial ForwardHigh
Chimeric Therapeutics raises $8.4M to fully fund CHM CDH17 CAR-T trial through Phase 1 amid strategic reset
23 Dec 2025 ·Capital Raising ·85
Chimeric Therapeutics Shows 75% Disease Control in Early CAR-T TrialMedium
Chimeric Therapeutics reports 75% disease control in CHM CDH17 Phase 1/2 trial with durable responses
13 Nov 2025 ·Clinical Trial Update ·85
Chimeric Therapeutics Reports 60% Complete Response in AML Phase 1B TrialMedium
Chimeric Therapeutics reports 60% complete response in Phase 1B AML trial with CHM CORE-NK
27 Apr 2026 ·Clinical Trial Update ·Unexpected ·85
Chimeric Therapeutics Secures FDA Orphan Drug Status for Gastric Cancer TherapyMedium
Chimeric Therapeutics awarded FDA Orphan Drug Designation for CHM CDH17 in gastric cancer
8 Dec 2025 ·Regulatory Announcement ·85
Chimeric Therapeutics Advances Trials Amid Cash Crunch and New PartnershipsMedium
Chimeric Therapeutics advances clinical trials, appoints new director, secures manufacturing partnership, faces cash runway under half a quarter
31 Oct 2025 ·Quarterly Activities Report and Appendix 4C ·80
Chimeric Therapeutics Advances CAR-T Therapy to Dose Level 2 with Early Tumor ShrinkageMedium
Chimeric Therapeutics Advances CHM CDH17 CAR-T to Dose Level 2 with Encouraging Early Clinical Results
4 Aug 2025 ·Clinical Trial Update ·80
Chimeric Therapeutics Clarifies Timing of Key AML Trial Data Amid ASX QueryMedium
Chimeric Therapeutics clarifies timing and materiality of ADVENT-AML trial data disclosures following ASX query
6 Nov 2025 ·ASX Query Response ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.